subject: China Api Obvious Advantages In The International Market [print this page] In recent years, rapid development of China's pharmaceutical industry, bulk drugs and pharmaceutical intermediates, as the world's largest supplier, China has established its strong international position.
China has registered more than 7,100 pharmaceutical enterprises, through more than 4,000 GMP certification, the State Food and Drug Administration registered more than 1,600 raw material drug production enterprises, access to raw materials for drug GMP certification has more than 3700 months.
2009 Chinese industrial output in China reached 940.3 billion yuan, up 21%. From the production side, China can produce more than 1500 kinds of chemical raw, capacity 200 million tons, about the global output of 1 / 5 over. In recent years, raw material industry has maintained steady growth, yield an average annual growth rate of 10% or more, has become the backbone of China's pharmaceutical industry. From the export side, China's exports of medicine and health products for more than half are API products. From 2002 to 2008, average annual growth rate of China's export of bulk drugs are more than 24% only in 2009 by the financial crisis, exports declined, but still reached 16.559 billion U.S. dollars.
2009, China's total import and export APIs 24.271 billion U.S. dollars, up 2.89%, accounting for 45.67% of total Chinese imports and exports. Among them, exports 16.559 billion U.S. dollars, up 4.53% in 2008 down; imports amounted to 7.713 billion U.S. dollars, an increase of 23.46%. The profound impact of the financial crisis, and after the pharmaceutical industry and the tireless efforts of enterprises, export volume maintained a 6.90% increase, the focus of intense market competition and shrinking market economy has brought prices down, leading to exports there the first decline in nearly a decade.
2009 years Pharmaceutical export performance of enterprises 8385, an increase of 5.49%. In which more than 10 million U.S. dollars in export value were 367, Zhejiang Medicine Co., Ltd., Shijiazhuang Pharma Weisheng Pharmaceutical, Zhejiang Medicines & Health Products Import & Export Co., Ltd., Northeast Pharmaceutical Factory, Jiangsu Jiangshan Pharmaceutical Co., Ltd. Zhuhai United Laboratories Co., Ltd., Hebei Weier Kang Pharmaceutical Co., Ltd. and other 13 enterprises in export volume more than 1 million. More than 100 million U.S. dollars in exports of these 13 enterprises, 11 enterprises in export growth, and there are four companies more than 30%, reflecting conditions in the financial crisis, major corporate growth conditions were good.
2009, China exported to the API 181 countries and regions, focusing on export markets in Asia, in Europe and North America, the three major export markets, exports accounted for a total of 87.4% bulk drug exports. Among them, the Asian export market, an increase of more than 14%, exports increased slightly, exports and exports European and American markets have declined, but modest changes in market share, down only about 1%. Fast development of the African market, exports increased by over 14% increase in exports is 30%, and Latin America exports more than 30% growth rate, indicating that the impact of financial crisis on the developed countries a larger share of development countries and emerging markets, the impact is relatively small.
API from 2009, import and export of China, China's export of bulk drugs market stability, market share in Asia and Europe and the United States is still more than 85%, top 10 export destination countries 8 for the developed countries, developing countries only India and Brazil, accounting for raw material medicine for over 60% of total exports. By the financial crisis, developed pharmaceutical market shrank, the United States, Japan, Netherlands, Italy, Belgium, Spain, 6 countries, exports have dropped by a decline in the United States reached more than 20%, while emerging market India and Brazil's exports continued to grow, which exports to India increased by 40%. Meanwhile, the financial crisis led to decreased exports of pharmaceutical products, domestic enterprises to adapt to the economic policy of expanding domestic demand, imports have business development. In 2009, China imports amounted to 7,713,000,000 U.S. dollars, up 23.46%, the main import market is still Japan, the U.S., South Korea, Belgium and Taiwan, accounting for my share of API imports more than 46%.
